UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

Blood, 2022-11, Vol.140 (Supplement 1), p.9029-9031

2022

Link zum Volltext

Verfügbarkeit prüfen

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

Blood, 2022-11, Vol.140 (Supplement 1), p.8954-8956

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

Blood, 2022-11, Vol.140 (Supplement 1), p.809-811

2022

Link zum Volltext

Verfügbarkeit prüfen

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Blood, 2022-11, Vol.140 (Supplement 1), p.11788-11790

2022

Link zum Volltext

Verfügbarkeit prüfen

Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials

Blood, 2022-11, Vol.140 (Supplement 1), p.3301-3303

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

Blood, 2021-11, Vol.138 (Supplement 1), p.4504-4504

2021

Link zum Volltext

Verfügbarkeit prüfen

Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML

Blood, 2021-11, Vol.138 (Supplement 1), p.794-794

2021

Link zum Volltext

Verfügbarkeit prüfen

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Improves Transfusion Requirement in Bone Marrow Failure Syndromes

Blood, 2021-11, Vol.138 (Supplement 1), p.3875-3875

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Blood, 2022-11, Vol.140 (Supplement 1), p.6064-6066

2022

Link zum Volltext

Verfügbarkeit prüfen

Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results

Blood, 2022-11, Vol.140 (Supplement 1), p.3250-3252

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

Blood, 2022-11, Vol.140 (Supplement 1), p.3196-3198

2022

Link zum Volltext

Verfügbarkeit prüfen

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis

Blood, 2020-11, Vol.136 (Supplement 1), p.41-42

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors

Blood, 2020-11, Vol.136 (Supplement 1), p.42-44

2020

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors

Blood, 2020-11, Vol.136 (Supplement 1), p.25-26

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 97

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals

KollektionTaylor & Francis:Master (3349 titles)

Zeitschrift / SerieInternational Archives Of The Photogrammetry, Remote Sensing And Spatial Information Sciences.

Zeitschrift / SerieBlood

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)

Publikationsform

Artikel
(97)

Sprache

Englisch
(97)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Cladribine with Low Dose Cytarabine for Unfit Patients: A Safe and Effective Approach with Low Early Mortality in a Population Ineligible for Clinical Trials

IL-18 mediates sickle cell cardiomyopathy and ventricular arrhythmias

Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas

Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Improves Transfusion Requirement in Bone Marrow Failure Syndromes

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years

The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up

Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis

Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors

Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors

Aktive Filter

Suchergebnisse filtern